Cyclin-dependent kinases (CDKs) are key enzymes in driving cells through the cell cycle into mitosis. Their activity is tightly controlled by phosphorylation and dephosphorylation of the CDK itself and association with regulatory subunits. Binding of a specific cyclin is a prerequisite for kinase activity. On the other hand, CDK inhibitory subunits have been recently described. p21 and p27 share a region of homology, and form with CDK and cyclins ternary complexes that can inhibit a variety of CDKs (Polyak et al., 1994; Nasmyth and Hunt, 1993) . p16INK4 was the first identified member (Serrano et al., 1993) of a growing family of proteins that specifically inhibit CDK4 and CDK6 (Kamb et al., 1994; Nobori et al., 1994; Hannon and Beach, 1994) . These two CDKs act together with cyclin D to control Rb phosphorylation and passage through the starting point of the cell cycle. This is a crucial step in controlling cell growth and perturbation of this pathway is thought to be implicated in carcinogenesis (Kamb et al., 1994) . Moreover, the gene encoding p16 protein, (p16 NK4/CDKN/ MTSI) has been recently located in the chromosomal region 9p2l, a critical area of allelic loss in a wide spectrum of human tumours (Serrano et al., 1993; Kamb et al., 1994; Nobori et al., 1994) . Interestingly, a high frequency of homozygous deletions in the p16INK4 gene in cell lines derived from a variety of human tumours including bladder and kidney have been reported (Kamb et al., 1994) . The mutation rate found in cell lines could even rival that of the p53 tumour-suppressor gene. However, in primary tumours the rate of p161NK4 mutations seems to be rather low and varies in a tumour type-dependent manner (Mori et al., 1994; Cairns et al., 1994; Spruck et al., 1994) .
Here we investigated the alterations of p16 NK4 in cell lines and primary tumours of the prostate using the polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis.
Materials and methods
Patient samples, cell lines and DNA isolation Four established prostatic cell lines (PC3, DU145, TSUprl, LNCaP) were grown in RPMI medium containing 10% of calf serum until they reach confluence. DNA was extracted according to Miller et al. (1988) . Twenty prostate cancer samples of various Gleason grades (Gg2-GgS) were obtained by transurethral resection of the prostate, and then frozen in liquid nitrogen. Areas containing at least 70% of tumour cells as judged by step sectioning, were subjected to DNA extraction (Miller et al., 1988) .
Polymerase chain reaction (PCR)
We amplified exon 1 and exon 2 for the analysis of p16INK4 gene alterations in prostate cancer. Primer sequences used for amplification were: 5'-GAAGAAGAGGAGGGGCTG-3' and 5'-GCGCTACCTGATTCCAATTC-3' for exon 1. Two overlapping primer sets were taken to cover the entire 500 bp long exon 2: 5'-GCAGCACCACCAGCGTGTCC-3' and 5'-GGAAATTGGAAACTGGAAGC -3'5'-TCTGTTCTCTCT-GGCAGGTC -3' and 5'-TCTGAGCTTTGGAAGCTCT -3'.
Purified DNA (50 ng) was amplified in a total volume of 50 pl using 50 pmol of sense and antisense primers, 200 gM of each dNTP, 1 x amplification buffer (17 mM ammonium sulphate, 67 mM Tris pH 8.8, 2 mm magnesium chloride, 10 mM P-mercaptoethanol, 6.7 gM EDTA), 2.5 mm magnesium chloride for exon 1, 1.5 mM magnesium chloride for exon 2 and 0.5 pl (2.5 unit) of Taq polymerase (Perkin Elmer). Dimethyl sulphoxide (5%) was added for each DNA amplification reaction. For SSCP analysis 0.3 pl dATP (370 MBq ml-', -10 TBq mmol-') was added to the reaction. Forty cycles of 50 s at 94°C, 40s at 61°C, 40 s at 72°C were carried out in a Perkin-Elmer thermal cycler. The PCR products were subsequently analysed by electrophoresis on 2% agarose gels.
SSCP analysis
The reaction product (3 Ml) was then mixed with 10 1l of loading buffer containing 96% formamide. Samples were denatured at 94°C for 3 min, chilled on ice for at least 5 min and 2,l was loaded onto a 6% non-denaturing polyacrylamide gel with or without 10% glycerol. Gels were electrophoresed at 5 W (with glycerol) and 3 W (without glycerol) for 16 h at room temperature, using 0.5 x Trisborate-EDTA buffer. Gels were dried and exposed to (RPN 8 Figure 1, sample 21) .
The corresponding PCR products were sequenced. This revealed a missense mutation in DU145 at codon 76 (GAC-.TAC) resulting in a change from aspartic acid to tyrosine (see example in Figure 2 ). The shift found in one of the primary tumours (case 166) was a mutation at codon 55 (CTG-+CCG) leading to a change from leucine to proline. It remains to be determined whether the substitution of the Asp with Tyr and Leu with Pro at codons 76 and 55 respectively plays a part in prostate cancer development. The shift in the other primary tumour (case 154) corresponded to a GCG-+ACG transition at codon 140 leading to a change from alanine to threonine. This change was previously reported and is thought to represent a polymorphism as it has also been found in white blood cells (Spruck et al., 1994) .
Genetic aberrations involved in prostate cancer have been taken into consideration previously and partly studied. Likewise, loss of heterozygosity (LOH) studies, identifying chromosomal regions harbouring potential tumour-suppressor genes, have mainly revealed 8p, 10q, 13q, 16q and 18q (Bergerheim et al., 1991; Bova et al., 1993; Phillips et al., 1994) . However, most LOH studies are limited to the analysis of a few chromosomes leaving the major part of the genome unexamined. Recently, genetic changes in primary and recurrent prostate cancer were analysed by comparative genomic hybridisation (CGH) (Visakorpi et al., 1995) , a new technique enabling the survey of the entire genome for gains and losses of DNA sequences (du Manoir et al., 1993) . Losses most often involved 8p (32%), 13q (32%), 6q (22%), 16q (19%), 18q (19%) and 9p (16%) (Visakorpi et al., 1995) . Hence, the frequency of 9p losses seems higher than the frequency of p16 mutations we found in this study, suggesting that another gene is the major target on 9p.
At present, the role played by the p16INK4 gene in human cancer remains controversial. For instance, in a recent study using primary tumours from a variety of organ types, which were previously shown to have loss of heterozygosity involving 9p21 -p22, p16 mutations were found in less than 3% (Cairns et al., 1994) . Mutations within the non-coding region, rearrangement and down-regulation of p16 could play a role in the inactivation of this gene in some cases (Cheng et al., 1994) . Furthermore, mutations within the promoter region may alter the normal expression of the p16 gene, although this type of mutation has not been reported to be a predominant mechanism of gene inactivation in human cancer (Cairns et al., 1994 (Cairns et al., 1994) revealed p16INK4 mutations in only a small fraction of primary tumours. Alternatively, higher frequencies have been found in some tumour types: 16% in head and neck squamous cell carcinoma and up to 51 % in oesophageal squamous cell carcinomas have been detected recently (Mori et al., 1994) . Therefore, the pl6INK4 gene has certainly a key role in certain cases, but not in all tumour from cytidine to adenosine in the non-coding strand is indicated by an arrow. This base substitution leads to a change from guanine to thymine at codon 76 and results in an amino acid change from aspartic acid to tyrosine.
